Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol

BACKGROUND: Hodgkin’s lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) are the two most common tumors expressing CD30. Internationally, a clinical study that is being conducted involving adults with recurrent or refractory HL or ALCL suggests efficacy of brentuximab vedotin (SGN-35). Pediatri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Sekimizu, Masahiro, Iguchi, Akihiro, Mori, Tetsuya, Koga, Yuhki, Kada, Akiko, Saito, Akiko M., Horibe, Keizo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5796474/
https://ncbi.nlm.nih.gov/pubmed/29390984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4042-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados